255 related articles for article (PubMed ID: 17986678)
1. Galantamine for the treatment of cognitive impairments in people with schizophrenia.
Buchanan RW; Conley RR; Dickinson D; Ball MP; Feldman S; Gold JM; McMahon RP
Am J Psychiatry; 2008 Jan; 165(1):82-9. PubMed ID: 17986678
[TBL] [Abstract][Full Text] [Related]
2. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia.
Dyer MA; Freudenreich O; Culhane MA; Pachas GN; Deckersbach T; Murphy E; Goff DC; Evins AE
Schizophr Res; 2008 Jul; 102(1-3):88-95. PubMed ID: 18325740
[TBL] [Abstract][Full Text] [Related]
3. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
Lindenmayer JP; Khan A
Schizophr Res; 2011 Feb; 125(2-3):267-77. PubMed ID: 20850275
[TBL] [Abstract][Full Text] [Related]
4. The effects of galantamine on psychopathology in chronic stable schizophrenia.
Conley RR; Boggs DL; Kelly DL; McMahon RP; Dickinson D; Feldman S; Ball MP; Buchanan RW
Clin Neuropharmacol; 2009; 32(2):69-74. PubMed ID: 18978489
[TBL] [Abstract][Full Text] [Related]
5. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
Lee SW; Lee JG; Lee BJ; Kim YH
Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
[TBL] [Abstract][Full Text] [Related]
6. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
7. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation.
Sharma T; Reed C; Aasen I; Kumari V
Schizophr Res; 2006 Jul; 85(1-3):73-83. PubMed ID: 16797163
[TBL] [Abstract][Full Text] [Related]
8. Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.
Kelly DL; McMahon RP; Weiner E; Boggs DL; Dickinson D; Conley RR; Buchanan RW
Schizophr Res; 2008 Aug; 103(1-3):161-8. PubMed ID: 18550339
[TBL] [Abstract][Full Text] [Related]
9. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study.
Sumiyoshi T; Park S; Jayathilake K; Roy A; Ertugrul A; Meltzer HY
Schizophr Res; 2007 Sep; 95(1-3):158-68. PubMed ID: 17628435
[TBL] [Abstract][Full Text] [Related]
10. A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.
Haig GM; Bain EE; Robieson WZ; Baker JD; Othman AA
Am J Psychiatry; 2016 Aug; 173(8):827-35. PubMed ID: 26940805
[TBL] [Abstract][Full Text] [Related]
11. Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy.
Deutsch SI; Schwartz BL; Schooler NR; Brown CH; Rosse RB; Rosse SM
Schizophr Res; 2013 Aug; 148(1-3):138-44. PubMed ID: 23768813
[TBL] [Abstract][Full Text] [Related]
12. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
Lee BJ; Lee JG; Kim YH
J Psychopharmacol; 2007 Jun; 21(4):421-7. PubMed ID: 17092979
[TBL] [Abstract][Full Text] [Related]
13. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.
Keefe RS; Malhotra AK; Meltzer HY; Kane JM; Buchanan RW; Murthy A; Sovel M; Li C; Goldman R
Neuropsychopharmacology; 2008 May; 33(6):1217-28. PubMed ID: 17625502
[TBL] [Abstract][Full Text] [Related]
15. The effect of galantamine added to clozapine on cognition of five patients with schizophrenia.
Bora E; Veznedaroğlu B; Kayahan B
Clin Neuropharmacol; 2005; 28(3):139-41. PubMed ID: 15965314
[TBL] [Abstract][Full Text] [Related]
16. WAIS-IV profile of cognition in schizophrenia.
Michel NM; Goldberg JO; Heinrichs RW; Miles AA; Ammari N; McDermid Vaz S
Assessment; 2013 Aug; 20(4):462-73. PubMed ID: 23443820
[TBL] [Abstract][Full Text] [Related]
17. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
[TBL] [Abstract][Full Text] [Related]
18. Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature.
Ribeiz SR; Bassitt DP; Arrais JA; Avila R; Steffens DC; Bottino CM
CNS Drugs; 2010 Apr; 24(4):303-17. PubMed ID: 20297855
[TBL] [Abstract][Full Text] [Related]
19. Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia.
Sacco KA; Creeden C; Reutenauer EL; George TP
Schizophr Res; 2008 Aug; 103(1-3):326-7. PubMed ID: 18571377
[No Abstract] [Full Text] [Related]
20. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia, II: convergent/discriminant validity and diagnostic group comparisons.
Hobart MP; Goldberg R; Bartko JJ; Gold JM
Am J Psychiatry; 1999 Dec; 156(12):1951-7. PubMed ID: 10588410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
